Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study

Objective: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, combining these therapies may favor prognosis in patients with a major disease presentation. We conducted a retrospec...

Full description

Bibliographic Details
Main Authors: Renée Ysermans, Matthias H. Busch, Joop P. Aendekerk, Jan G.M.C. Damoiseaux, Pieter van Paassen
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Journal of Translational Autoimmunity
Subjects:
ANCA
Vasculitis
Rituximab
Cyclophosphamide
Relapse
Outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909022000399

Internet

http://www.sciencedirect.com/science/article/pii/S2589909022000399

Similar Items